Emrusolmin Anle138b|cas:882697-00-9|西域试剂

Emrusolmin Anle138b,99.96%

产品编号：Bellancom-101855| CAS NO：882697-00-9| 分子式：C₁₆H₁₁BrN₂O₂| 分子量：343.17

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-101855	￥660.00	杭州北京（现货）
Bellancom-101855	￥1100.00	杭州北京（现货）
Bellancom-101855	￥2400.00	杭州北京（现货）
Bellancom-101855	￥4200.00	杭州北京（现货）
Bellancom-101855	￥7400.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Emrusolmin Anle138b

产品介绍

Emrusolmin (Anle138b) 是一种低聚物聚集抑 (oligomeric aggregation ) 调节剂，可阻断朊病毒蛋白 (PrPSc) 和 α-突触核蛋白 (α-syn) 病理性聚集的形成。Emrusolmin 在体内强烈抑制低聚物积累、神经元变性和疾病进展。Emrusolmin 毒性低，口服生物利用度高，血脑屏障通透性好。Emrusolmin 阻断 Aβ 通道并挽救淀粉样变性小鼠模型的疾病表型。

生物活性

Emrusolmin (Anle138b), an oligomeric aggregation inhibitor, blocks the formation of pathological aggregates of prion protein (PrPSc) and of α-synuclein (α-syn). Emrusolmin strongly inhibits oligomer accumulation, neuronal degeneration, and disease progression in vivo. Emrusolmin has low toxicity and an excellent oral bioavailability and blood-brain-barrier penetration. Emrusolmin blocks Aβ channels and rescues disease phenotypes in a mouse model for amyloid pathology.

体外研究

Oligomeric aggregates are presumed to be the key neurotoxic agent. Emrusolmin blocksthe formation of pathological aggregates of prion protein and of α-synuclein, which is deposited in Parkinson’s disease and other synucleinopathies such as dementia with Lewy bodies and multiple system atrophy. Emrusolmin strongly inhibits all prion strains tested including BSE-derived and human prions. Emrusolmin shows structure-dependent binding to pathological aggregates and strongly inhibits formation of pathological oligomers both for prion protein and α-synuclein.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Emrusolmin shows structure-dependent binding to pathological aggregates and strongly inhibits formation of pathological oligomers in vitro and in vivo both for prion protein and α-synuclein.
Emrusolmin (0.6-2 g/kg; p.o.) modulates α‐synuclein oligomerization.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Two‐month‐old PLP‐hαSyn mice
Dosage:	0.6 and 2 g/kg
Administration:	Oral
Result:	Prevented motor deficits and neurodegeneration in the PLP‐hαSyn mice.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Two‐month‐old PLP‐hαSyn mice
Dosage:	0.6 and 2 g/kg
Administration:	Oral
Result:	Prevented motor deficits and neurodegeneration in the PLP‐hαSyn mice.

性状

Solid

溶解性数据

In Vitro:

DMSO : ≥ 50 mg/mL (145.70 mM)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.9140 mL	14.5700 mL	29.1401 mL
5 mM	0.5828 mL	2.9140 mL	5.8280 mL
10 mM	0.2914 mL	1.4570 mL	2.9140 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (7.29 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (7.29 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (7.29 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (7.29 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。